Quotient Ltd (NASDAQ:QTNT) posted its quarterly earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.55), Bloomberg Earnings reports. The company had revenue of $6.83 million during the quarter, compared to analyst estimates of $5.70 million.
Quotient (NASDAQ:QTNT) traded down 8.44% during mid-day trading on Friday, reaching $3.58. 337,824 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $5.82 and its 200 day moving average price is $6.59. Quotient has a 12 month low of $3.52 and a 12 month high of $8.64. The stock’s market capitalization is $51.47 million.
ILLEGAL ACTIVITY NOTICE: “Quotient Ltd (NASDAQ:QTNT) Posts Earnings Results, Meets Expectations” was originally reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/quotient-limited-nasdaqqtnt-announces-earnings-results-updated.html.
Several analysts recently issued reports on the stock. ValuEngine raised shares of Quotient from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th. Zacks Investment Research raised shares of Quotient from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th.
In other Quotient news, insider D J. Paul E. Cowan sold 9,420 shares of Quotient stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $6.11, for a total transaction of $57,556.20. Following the completion of the transaction, the insider now directly owns 26,666 shares of the company’s stock, valued at $162,929.26. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider D J. Paul E. Cowan sold 54,460 shares of Quotient stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $4.06, for a total value of $221,107.60. Following the transaction, the insider now directly owns 26,666 shares of the company’s stock, valued at $108,263.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 220,072 shares of company stock valued at $1,282,778. 29.00% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of QTNT. New York State Common Retirement Fund bought a new position in shares of Quotient during the second quarter worth about $101,000. Goldman Sachs Group Inc. bought a new position in shares of Quotient during the second quarter worth about $104,000. Nationwide Fund Advisors acquired a new stake in shares of Quotient during the second quarter worth $111,000. Nicholas Hoffman & Company LLC. acquired a new stake in shares of Quotient during the first quarter worth $150,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Quotient during the second quarter worth $177,000. 38.97% of the stock is owned by institutional investors.
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd and related companies with MarketBeat.com's FREE daily email newsletter.